Abstract

Although various mechanisms of castration-resistant prostate cancer (CRPC) have been discovered, reliable biomarkers for monitoring CRPC progression are lacking. We sought to identify molecules that predict the progression of advanced prostate cancer (AdvPC) into CRPC. The study used primary-site samples (N=45 for next-generation sequencing (NGS); N=243 for real-time polymerase chain reaction) from patients with prostate cancer (PC). Five public databases containing microarray data of AdvPC and CRPC samples were analyzed. The NGS data showed that each progression step in PC associated with distinct gene expression profiles. Androgen receptor (AR) associated with tumorigenesis, advanced progression, and progression into CRPC. Analysis of the paired and unpaired AdvPC and CRPC samples in the NGS cohort showed that 15 genes associated with progression into CRPC. This was validated by cohort-1 and public database analyses. Analysis of the third cohort with AdvPC showed that higher serine peptidase inhibitor, Kazal type 1 (SPINK1) and lower Sp8 transcription factor (SP8) expression associated with progression into CRPC (log-rank test, both P<0.05). Multivariate regression analysis showed that higher SPINK1 (Hazard Ratio (HR)=4.506, 95% confidence intervals (CI)=1.175–17.29, P=0.028) and lower SP8 (HR=0.199, 95% CI=0.063–0.632, P=0.006) expression independently predicted progression into CRPC. Gene network analysis showed that CRPC progression may be mediated through the AR-SPINK1 pathway by a HNF1A-based gene network. Taken together, our results suggest thatSPINK1 and SP8 may be useful for classifying patients with AdvPC who have a higher risk of progressing to CRPC.

Highlights

  • Prostate cancer (PC) is currently the most common malignancy in males [1]

  • Unsupervised hierarchical clustering analysis yielded three main sample clusters that consisted of all benign prostate hyperplasia (BPH) samples, all localized PC (T2 or T3 N0 M0) samples, and all advanced PC (AdvPC) (T4 or any N1/M1) plus castration-resistant prostate cancer (CRPC) samples (Supplementary Figure 1)

  • As AdvPC progresses into CRPC, only a few genes change their expression significantly

Read more

Summary

Introduction

About 20% of all PC patients will present with or develop disease progression and metastasis [2, 3] For patients with such advanced PC (AdvPC), the therapeutic options include prostatectomy, radiation therapy, and/or androgendeprivation therapy (ADT) [4]. Despite these therapies, the prognosis of AdvPC remains poor: for example, the 5-year survival rate of patients with AdvPC who are treated with ADT is 23–26% [3]. This is because ADT can only induce short 2–3 year remissions since most PCs eventually develop into castration-resistant prostate cancer (CRPC) [3].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call